Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HR positive + BRCA2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

2099; 5241; 675

Related biomarkers:

‹

›

HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B
HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4